REBIScan

About REBIScan

Based in Boston, Massachusetts, Rebion is a medical device company focused on identifying brain-related health issues through neuro-ocular scanning. Founded in 2009 by David G. Hunter, MD, PhD, the company is built upon years of research from prominent medical institutions. Dr. Hunter, who serves as the company's Chairman and is the Ophthalmologist-in-Chief at Boston Children's Hospital and Vice-Chair of Ophthalmology at Harvard Medical School, co-invented the core technology. Co-founder Justin Shaka, who was previously with Boston Children's Hospital, holds the position of CEO.

The company's core offering is its Neural Performance Scanning (NPS) platform, which uses proprietary laser technology to analyze the connection between the eye and the brain. This technology measures retinal fixation and saccadic movement to detect functional impairments in the brain that manifest as vision problems. The principle behind NPS is that the eyes provide a "window to the brain," allowing for non-invasive assessment of neurological health.

Rebion's first commercial product, the blinq® vision scanner, received FDA clearance and was launched in 2020. This portable device performs a 3-second scan to detect amblyopia (lazy eye) and strabismus in children, which are leading causes of pediatric vision loss. The device is designed for ease of use by both medical professionals and trained laypeople, facilitating screenings in clinics and community settings. To support its commercial activities, Rebion has established a direct sales team and is exploring global distribution partnerships, with a manufacturing agreement in place with Canon Virginia, Inc. since 2021. The company's business model is diversified, including point-of-care sales, patient monitoring services, and the potential for AI-assisted cloud-based data for research.

Building on the NPS platform, Rebion is developing its next product, the Traq™ device, for the detection and monitoring of Traumatic Brain Injury (TBI). The company has received funding from the National Institutes of Health (NIH) to support clinical trials for TBI, which are anticipated to conclude in 2025. Rebion has raised over $17 million in funding, including significant grants from the NIH, to advance its clinical trials and expand its sales organization. The firm holds a substantial intellectual property portfolio, with 7 issued U.S. patents and 23 international patents.